

Government of Western Australia North Metropolitan Health Service Women and Newborn Health Service



ADULT MEDICATION GUIDELINE

TRIMETHOPRIM WITH SULFAMETHOXAZOLE

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the **Disclaimer**.

Quick Links									
<u>Dose</u>	Administration	<u>Monitoring</u>	Pregnancy and Breastfeeding						
Restrictions									
Antimicrobial restriction : Restricted (IV)									
Antimicrobial restriction: Unrestricted (Oral)									
Medication Class									
Antibacterial									
Presentation									
Tablet: Trimethoprim 160 mg with sulfamethoxazole 800 mg Suspension: Trimethoprim 8 mg/mL with sulfamethoxazole 40 mg/mL Ampoule: Trimethoprim 80 mg/5mL with sulfamethoxazole 400 mg/5mL									
Storage									
Tablet/suspension: Store below 30°C. Protect form light. Ampoule: Store below 30°C. Do not refrigerate. Protect from light.									
Dose	Schedule 8 Medication								
Mild-to-Moderate infections									
Oral:									
160/800mg every 12 hours									
Severe infections									

IV:

160/800 - 320/1600mg every 12 hours

Administration

Refer to the Australian Injectable Drugs Handbook

IV infusion

Step 1 Dilution:

Dilute to 1 in 25 with a sodium chloride 0.9% or glucose 5% solution

e.g. For a 160/800mg dose, dilute 10mL (2 ampoules) to 250mL

Step 2 Administration:

Infuse over 60 to 90 minutes

<u>Oral</u>

Take with or soon after food.

Avoid excessive skin exposure to sunlight.

Monitoring

Complete blood count and folate status during prolonged or high dose

Serum potassium, beginning day 3 if patient has renal impairment, taking drugs causing hyperkalaemia or high dose

Renal function during prolonged treatment, if history or renal insufficiency

Contraindicated by the manufacturer if CrCl <15 mL/minute

Contraindicated in severe hepatic impairment

Pregnancy

1st Trimester: Consider alternative

2nd Trimester: Consider alternative

3rd Trimester: Consider alternative

Avoid in the 1st trimester when possible. Trimethoprim, a folic acid antagonist, has been associated with an increased risk of congenital malformations. Concurrent maternal supplementation with folic acid 5mg daily is recommended

Breastfeeding

Considered safe to use in healthy infants

Use with caution if infant is premature, ill or jaundiced

Avoid if infant has G6PD deficiency

Comments

Also known as co-trimoxazole

Ratio of trimethoprim to sulfamethoxazole is 1:5

Doses are expressed as: 160/800 mg = trimethoprim 160 mg with sulfamethoxazole 800 mg

8/40 mg is equivalent to 1 mL of oral liquid

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

Urinary Tract Infection for Pregnant Women

Infections in Obstetrics (Intra-amniotic Chorioamnionitis and Postpartum Infection): Diagnosis and management

Perineal Care and Repair: Protection, Assessment and Management

Antimicrobial Stewardship

Antimicrobial Restriction Category Risk

References

Australian Medicines Handbook. Trimethoprim-sulfamethoxazole. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Dec 22]. Available from: https://amhonline.amh.net.au/

Therapeutic Guidelines. Drug use in pregnancy and breastfeeding. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2021 [cited 2021 Dec 22]. Available from: https://tgldcdp-tg-org-au.kelibresources.health.wa.gov.au/etgAccess

The Royal Women's Hospital. Trimethoprim with Sulfamethoxazole. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Dec 22]. Available from: https://thewomenspbmg.org.au/

MIMS Australia. Trimethoprim-Sulfamethoxazole. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2021 Dec 21]. Available from: https://www.mimsonline.com.au

Keywords	Trimethoprim with sulfamethoxazole, co-trimoxazole, septrin, sulfamethoxazole- trimethoprim combination, trimethoprim, MRSA, antibiotic, sepsis, trimethoprim compound, UTI, urinary tract infection, sulfamethoxazole, sulphamethoxazole, MRSA, TMP-SMZ							
Document Owner:	Chief Pharmacist							
Author/ Reviewer	KEMH Pharmacy Department							
Version Info:	4.0							
Date First Issued:	Nov 2014	Last Reviewed:	Feb 2022		Review Date:	Feb 2025		
Endorsed by:	Medicines and Therapeutics Committee				Date:	01/03/2022		
NSQHS Standards Applicable:	Std 1: Clinical Governance			Std 5: Comprehensive Care				
	Std 2: Partnering with Consumers			Std 6: Communicating for Safety				
	Std 3: Preventing and Controlling Healthcare Associated Infection			Std 7: Blood Management				
	Std 4: Medication Safety			Std 8: Recognising and Responding to Acute Deterioration				
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.								

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.